Neither source provides structured incidence for vaginal dryness, vulvovaginitis, BV, dyspareunia, discharge changes, or atrophy
About four in ten adults ages 50 to 64 and 65 and older say they have heard a lot about GLP-1 drugs, compared to about one-third of adults ages 30-49 (32%) and one in six adults ages 18-29 (17%)
During these initial stages, you may experience a gradual reduction in appetite, decreased cravings, and lower caloric intake, all of which contribute to early success
Orforglipron is not currently FDAapproved or commercially available
When activated, it: - Reduces appetite - Slows gastric emptying - Lowers blood glucose - Increases satiety - Improves insulin sensitivity The peptides in PEP R, PEP S, and PEP T harness this naturally occurring pathwayoffering patients support without harsh stimulants or unsafe quick-fixes
Lobo, V., Patil, A., Phatak, A., & Chandra, N